Home Coronavirus Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient on Private Insurance

Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient on Private Insurance

Remdesivir’s pricing has been hotly debated. Here, a lab technician works on the drug at a facility in Cairo, Egypt, June 25. PHOTO: AMR ABDALLAH DALSH/REUTERS

Gilead Sciences Inc. GILD -1.22% detailed its pricing plans for Covid-19 drug remdesivir, saying it will charge U.S. hospitals $3,120 for a typical patient with commercial insurance.

The drugmaker on Monday disclosed its pricing plans as it prepares to begin charging for the drug in July. The U.S. has been distributing remdesivir donated by Gilead since the drug was authorized for emergency use in May.

Under the company’s plans, Gilead will charge a higher price for patients with private insurance in the U.S., and a lower price for U.S. government health programs like Medicare and all other developed countries that insure their patients directly.

The government price will be $390 per dose or $2,340 per patient for the shortest treatment course and $4,290 for a longer treatment course.

Gilead said in the U.S. it will charge nongovernment buyers such as hospitals about $520 per dose, or a third more than the government price, for patients who are commercially insured. That works out to $3,120 for a patient getting the shorter, more common course of treatment, and $5,720 for the longer treatment duration.

Wall Street Journal, excerpt posted on  SouthFloridaReporter.com, June 29, 2020